.jpeg)
When was moboxetinib approved for marketing?
On September 15, 2021, the U.S. Food and Drug Administration (FD A) Approvedmobosetinib, which was approved for marketing by China’s State Food and Drug Administration on 2023 3. Mobosetinib is currently approved in the United States, United Kingdom, Switzerland, South Korea, Australia and China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation whose disease has progressed during or after platinum-based chemotherapy. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
